Hepatitis C virus serologic and virologic tests and clinical diagnosis of HCV-related liver disease

International Journal of Medical Sciences

Volumn 3, Issue 2, 2006, Pages 35-40

  Chevaliez, Stéphane ^a,b   Pawlotsky, Jean Michel ^a,b,c,d,e,f  

^a HENRI MONDOR HOSPITAL   (France)

^b UNIVERSITÉ PARIS EST CRÉTEIL   (France)

^c INSTITUT PASTEUR   (France)

^d Universite Paris 1   (France)

^e European Association for the Study of the Liver (EASL)   (France)

^f Scientific College of the French National Agency for AIDS and Viral Hepatitis Research (ANRS)   (France)

Author keywords

HCV RNA; Hepatitis C virus; Serological and virological tests

Indexed keywords

HEPATITIS C ANTIBODY; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; RIBAVIRIN; VIRUS RNA;

ACUTE DISEASE; ANTIBODY DETECTION; CHRONIC DISEASE; DOSE RESPONSE; DRUG MEGADOSE; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; IMMUNOASSAY; LIVER DISEASE; MEDICAL DECISION MAKING; REVIEW; SEROLOGY; TREATMENT DURATION;

EID: 33646270395     PISSN: 14491907     EISSN: 14491907     Source Type: Journal    
DOI: 10.7150/ijms.3.35     Document Type: Review

References (29)

1. Pawlotsky JM. Use and interpretation of virological tests for hepatitis C. Hepatology 2002, 36 (Suppl 1): S65-73.
2. Colin C, et al. Sensitivity and specificity of third-generation hepatitis C virus antibody detection assays: an analysis of the literature. J Viral Hepat 2001, 8: 87-95.
3. Pawlotsky JM, et al. What strategy should be used for diagnosis of hepatitis C virus infection in clinical laboratories? Hepatology 1998, 27: 1700-2.
4. Pawlotsky JM, et al. Serological determination of hepatitis C virus genotype: comparison with a standardized genotyping assay. J Clin Microbiol 1997, 35: 1734-9.
5. Pawlotsky JM. Molecular diagnosis of viral hepatitis. Gastroenterology 2002, 122:1554-68.
6. Martell M, et al. High-throughput real-time reverse transcription-PCR quantitation of hepatitis C virus RNA. J Clin Microbiol 1999, 37:327-32.
7. Komurian-Pradel F, et al. Quantitation of HCV RNA using real-time PCR and fluorimetry. J Virol Methods 2001, 95: 111-9.
8. Simmonds P. Viral heterogeneity of the hepatitis C virus. J Hepatol 1999, 31 (Suppl 1): 54-60.
9. Simmonds P, et al. Consensus proposals for a unified system of nomenclature of hepatitis C virus genotypes. Hepatology 2005, 42: 962-73.
10. Germer JJ, et al. Automated sample preparation for the Trugene HIV-1 genotyping kit using the MagNA pure LC instrument. Diagn Microbiol Infect Dis 2004, 49: 59-61.
11. Stuyver L, et al. Second-generation line probe assay for hepatitis C virus genotyping. J Clin Microbiol 1996, 34: 2259-66.
12. Stuyver L, et al. Hepatitis C virus genotyping by means of 5′-UR/core line probe assays and molecular analysis of untypeable samples. Virus Res 1995, 38: 137-57.
13. Zheng X, et al. Direct comparison of hepatitis C virus genotypes tested by INNO-LiPA HCV II and TRUGENE HCV genotyping methods. J Clin Virol 2003, 28: 214-6.
14. Lavillette D, et al. Human serum facilitates hepatitis C virus infection, and neutralizing responses inversely correlate with viral replication kinetics at the acute phase of hepatitis C virus infection. J Virol 2005, 79: 6023-34.
15. [No authors listed]. EASL International Consensus Conference on Hepatitis C. Paris, 26-28, February 1999, Consensus Statement. European Association for the Study of the Liver. J Hepatol 1999, 30: 956-61.
16. Lok AS, et al. Antibody response to core, envelope and nonstructural hepatitis C virus antigens: comparison of immunocompetent and immunosuppressed patients. Hepatology 1993, 18: 497-502.
17. Thio CL, et al. Screening for hepatitis C virus in human immunodeficiency virus-infected individuals. J Clin Microbiol 2000, 38: 575-7.
18. [No authors listed]. NIH Consensus Statement on Management of Hepatitis C: 2002. NIH Consens State Sci Statements 2002, 19: 1-46.
19. Hadziyannis SJ, et al. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med 2004, 140: 346-55.
20. Castera L, et al. Prospective comparison of transient elastography, Fibrotest, APRI, and liver biopsy for the assessment of fibrosis in chronic hepatitis C. Gastroenterology 2005, 128: 343-50.
21. Poynard T, et al. FibroTest-FibroSURE: towards a universal biomarker of liver fibrosis? Expert Rev Mol Diagn 2005, 5: 15-21.
22. Davis GL, et al. Early virologic response to treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C. Hepatology 2003, 38: 645-52.
23. Fried MW, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002, 347: 975-82.
24. Zeuzem S, et al. Efficacy of 24 weeks treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C infected with genotype 1 and low pretreatment viremia. J Hepatol 2006, 44: 97-103.
25. Chung RT, et al. Peginterferon Alfa-2a plus ribavirin versus interferon alfa-2a plus ribavirin for chronic hepatitis C in HIV-coinfected persons. N Engl J Med 2004, 351: 451-9.
26. Pawlotsky JM. Treating hepatitis C in "difficult-to-treat" patients. N Engl J Med 2004, 351: 422-3.
27. Torriani FJ, et al. Peginterferon Alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients. N Engl J Med 2004, 351: 438-50.
28. Manns MP, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001, 358: 958-65.
29. Dalgard O, et al. Treatment with pegylated interferon and ribavarin in HCV infection with genotype 2 or 3 for 14 weeks: a pilot study. Hepatology 2004, 40: 1260-5.